ミッション
Missiion

日向(ひむか)の地から新しい医薬品を

ひむかAMファーマ株式会社は,宮崎大学医学部(旧・宮崎医科大学)で発見され,基礎研究・臨床研究が進められている生理活性ペプチド;アドレノメデュリン(Adrenomedullin, AM)の改良による創薬シーズの研究開発を実施し,Unmet Medical Needs の解消に貢献する創薬を目指します。

Challenge to novel drug development from Himuka*

We develop drug seeds with a strong focus on derivatives of a bioactive peptide adrenomedullin (AM) which was discovered at University of Miyazaki (formerly Miyazaki Medical College). Our drug seeds will make significant contributions to resolve unmet medical needs.

*Our name “Himuka AM” is named after “Himuka” and “Adrenomedullin” (for short AM).
Himuka is the old name for Miyazaki area of Japan at where Adrenomedullin was firstly discovered and has been researched, and we are. The meaning of Himuka is “facing to the rising sun”, which will reflect our growth.

Top